Hepatitis C Treatment and Barriers to Eradication

Monica A Konerman, Anna S F Lok, Monica A Konerman, Anna S F Lok

Abstract

Current treatment for chronic hepatitis C (CHC) is highly efficacious, well-tolerated, and of short duration for the majority of patients. Despite the dramatic advances in therapy, there remain several barriers to disease eradication. These include deficiencies in screening, diagnosis, and access to care, and high cost of the direct-acting antiviral medications. In addition, incident cases and reinfection associated with injection drug use contribute to the persistent worldwide disease burden. This article will review the current CHC treatments, and outline the remaining gaps in therapy and barriers to disease eradication.

Figures

Figure 1
Figure 1
Class I treatment recommendations for chronic hepatitis C. Treatment experienced defined as PEG-IFN/RBV only. †In GT1a, need to test for NS5A RAV for EBR; need 16 weeks of therapy with RBV for high-fold RAV. *RBV needed for GT1a but not GT1b in treatment-naive patients; RBV needed for all GT1 treatment-experienced patients. ^A total of 24 weeks of therapy required for treatment-experienced patients. +This regimen only applies to treatment-experienced patients. #RBV only needed in treatment-experienced patients. EBR, ebasvir; DAS, dasabuvir; DCV, daclatasvir; GT, genotype; GZR, grazoprevir; IFN, interferon; LDV, ledipasvir; PrO, paritaprevir+ritonavir+ombitasvir; RAV, resistance-associated variant; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; VEL, velpatasvir.
Figure 2
Figure 2
HCV care cascade and path to disease eradication: barriers and potential solutions. DAA, direct-acting antiviral; EMR, electronic medical record; HCV, hepatitis C virus; IDU, injection drug use; PCP, primary care physician.

References

    1. AASLD-IDSA. Recommendations for Testing, Managing, and Treating Hepatitis C; .
    1. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889–1898.
    1. Zeuzem S, Ghalib R, Reddy KR et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015; 163: 1–13.
    1. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993–2001.
    1. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211–221.
    1. Sulkowski MS, Eron JJ, Wyles D et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223–1231.
    1. Sulkowski MS, Vargas HE, Di Bisceglie AM et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 2016; 150: 419–429.
    1. Backus LI, Belperio PS, Shahoumian TA et al. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology 2016; 64: 405–414.
    1. Branchi F, Conti CB, Baccarin A et al. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2014; 20: 14568–14580.
    1. Wong GL, Wong VW, Choi PC et al. Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2009; 24: 1002–1007.
    1. Feld JJ, Zeuzem S. Sofosbuvir and velpatasvir for patients with HCV infection. N Engl J Med 2016; 374: 1688–1689.
    1. Pianko S, Flamm SL, Shiffman ML et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 2015; 163: 809–817.
    1. Konerman MA, Mehta SH, Sutcliffe CG et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014; 59: 767–775.
    1. Liu Z, Hou J. Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection. Int J Med Sci 2006; 3: 57–62.
    1. Potthoff A, Wedemeyer H, Boecher WO et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008; 49: 688–694.
    1. Conti F, Buonfiglioli F, Scuteri A et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol 2016; e-pub ahead of print 24 June 2016.
    1. Pol S. Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: the ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts). J Hepatol 2016; e-pub ahead of print 7 June 2016.
    1. Denniston MM, Jiles RB, Drobeniuc J et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014; 160: 293–300.
    1. Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J 2011; 30: 983–985.
    1. Poordad F, Gordon SC, Asatryan A et al High-efficacy of ABT-493 and ABT-530 in HCV genotype-1-infected patients who have failed direct-acting antiviral-containing regimens: the Magellan-1 study. The International Liver Congress, 13–17 April 2016, Barcelona, Abstract GS11.
    1. Kwo P. 100% SVR4 with ABT-493 and ABT-530 with or without Ribavirin in Treatment-Naïve HCV Genotype 3-Infected Patients with Cirrhosis. EASL International Liver Congress. 2016.
    1. Holmberg SD, Spradling PR, Moorman AC et al. Hepatitis C in the United States. N Engl J Med 2013; 368: 1859–1861.
    1. Yehia BR, Schranz AJ, Umscheid CA et al. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One 2014; 9: e101554.
    1. Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705–714.
    1. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 349–357.
    1. Smith BD, Morgan RL, Beckett GA et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1–32.
    1. Litwin AH, Smith BD, Drainoni ML et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis 2012; 44: 497–503.
    1. Adebajo CO, Aronsohn A, Te HS et al. Digestive Diseases Week 2015. Gastroenterology 2015; 148: S1101–1102.
    1. Sears DM, Cohen DC, Ackerman K et al. Birth cohort screening for chronic hepatitis during colonoscopy appointments. Am J Gastroenterol 2013; 108: 981–989.
    1. US Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care and treatment of viral hepatitis; .
    1. Konerman MA, Thomson M, Lok AS. Digestive Diseases Week 2016. Gastroenterology 2016; 150: S1159–1160.
    1. Reau N. HCV testing and linkage to care: expanding access. Clin Liver Dis 2014; 4: 31–34.
    1. Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat 2012; 19: 829–835.
    1. McGibbon E, Bornschlegel K, Balter S. Half a diagnosis: gap in confirming infection among hepatitis C antibody-positive patients. Am J Med 2013; 126: 718–722.
    1. Spradling PR, Tong X, Rupp LB et al. Trends in HCV RNA testing among HCV antibody-positive persons in care, 2003-2010. Clin Infect Dis 2014; 59: 976–981.
    1. Affairs DoV. Reflex Confirmatory Testing for Chronic Hepatitis C Virus Infection. VHA Directive;2009-063.
    1. Prevention CfDCa. Guidelines for laboratory testing and result reporting of antibody to hepatitis c virus. MMWR Recomm Rep 52:1–16.
    1. Organization WH. Access to hepatitis c medicines. Bull World Health Organ 2015;93:799–805.
    1. Lemoine M, Thursz M. Hepatitis C, a global issue: access to care and new therapeutic and preventive approaches in resource-constrained areas. Semin Liver Dis 2014; 34: 89–97.
    1. Moorman AC, Gordon SC, Rupp LB et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis 2013; 56: 40–50.
    1. McWilliam R, Dundas P, Fraser A. Follow-up of HCV patients referred to specialist services- where do they all go? Gut A46–A47.
    1. Stepanova M, Kanwal F, El-Serag HB et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53: 737–745.
    1. Falade-Nwulia O, Mehta SH, Lasola J et al. Public health clinic-based hepatitis C testing and linkage to care in Baltimore. J Viral Hepat 2016; 23: 366–374.
    1. Herrera JL. Patients with hepatitis C are best managed by a specialist in liver diseases. PRO: management of hepatitis C by liver disease specialists. Am J Gastroenterol 2007; 102: 1837–1839.
    1. Shiffman ML. A balancing view: we cannot do it alone. Am J Gastroenterol 2007; 102: 1841–1843.
    1. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 2010; 65: 1327–1329.
    1. McGovern BH. Editorial commentary: hepatitis C virus and the infectious disease physician: a perfect match. Clin Infect Dis 2012; 55: 414–417.
    1. Asrani SK, Davis GL. Impact of birth cohort screening for hepatitis C. Curr Gastroenterol Rep 2014; 16: 381.
    1. Thomson M, Konerman MA, Choxi H et al. Primary care physician perspectives on hepatitis C management in the era of direct-acting antiviral therapy. Dig Dis Sci 2016.
    1. Hepatitis C Online. Cost and Access to Direct-acting Antiviral Agents. 2016. .
    1. Saag MS. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. Clin Infect Dis 2015; 61: 169–170.
    1. Pollack A. Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion. New York Times, 3 February 2015.
    1. Barua S, Greenwald R, Grebely J et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015; 163: 215–223.
    1. McCombs JS, Tonnu-MiHara I, Matsuda T et al. O003: Can hepatitis c treatment be safely delayed? evidence from the veterans administration healthcare system. J Hepatol 2015; 62: S191.
    1. Zahnd C, Salazar-Vizcaya L, Dufour JF et al Impact of Deferring HCV Treatment on Liver-related Events in HIV+ Patients. Conference on Retroviruses and Opportunistic Infections (CROI). 2015.
    1. Leidner AJ, Chesson HW, Xu F et al. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015; 61: 1860–1869.
    1. Gilead Sciences. Chronic Hepatitis C Treatment Expansion: Generic Manufacturing for Developing Countries. 2015. .
    1. Akyar E, Seneca KH, Akyar S et al. Linkage to care for suburban heroin users with hepatitis C virus infection, New Jersey, USA. Emerg Infect Dis 2016; 22: 907–909.
    1. Zibbell JE, Iqbal K, Patel RC et al. Increases in hepatitis C virus infection related to injection drug use among persons aged ⩽30 years—Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep 2015; 64: 453–458.
    1. Martin NK, Vickerman P, Grebely J et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598–1609.
    1. Zickmund SL, Campbell SA, Tirado CF et al. Perceived barriers to hepatitis C therapy for patients receiving opioid agonist treatment. J Addict Med 2012; 6: 233–239.
    1. Walley AY, White MC, Kushel MB et al. Knowledge of and interest in hepatitis C treatment at a methadone clinic. J Subst Abuse Treat 2005; 28: 181–187.
    1. Simmons B, Saleem J, Hill A et al. Risk of late relapse or reinfection with hepatitis c virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016.
    1. Organization WH. Draft Global Health Sector Strategies: Viral Hepatitis, 2016-2021. 2016.
    1. Buckley GJ, Strom BL; Committee on a National Strategy for the Elimination of Hepatitis B and C. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. National Academies Press: Washington, DC, 2016.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다